Comparing R-Bendamustine vs. R-CHOP Plus Maintenance Therapy as First-Line Systemic Treatment in Follicular Lymphoma: A Multicenter Retrospective GELTAMO Study

Mariana Bastos-Oreiro,Antonio Gutierrez,Almudena Cabero,Javier López,Paola Villafuerte,Ana Jiménez-Ubieto,Raquel de Oña,Adolfo De la Fuente,Belén Navarro,Javier Peñalver,Pilar Martínez,Carmen Alonso,María Infante,Raúl Córdoba,Blanca Perez-Montero,Jaime Pérez de Oteyza,Sonia González de Villambrosio,Paula Fernández-Caldas,Raquel del Campo,Daniel García Belmonte,Javier Diaz-Gálvez,Antonio Salar,Juan-Manuel Sancho

DOI: https://doi.org/10.3390/cancers16071285

2024-03-27

Cancers

Abstract:Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and R-bendamustine (R-B) are the most common frontline treatment strategies for advanced-stage follicular lymphoma (FL). After R-CHOP induction therapy, using rituximab for maintenance therapy notably improves outcomes; however, whether this can be achieved by using the same approach after R-B therapy is still being determined. This retrospective analysis compared 476 FL patients from 17 GELTAMO centers who received R-based regimens followed by rituximab maintenance therapy for untreated advanced-stage FL. The complete response rate at the end of induction was higher with R-B and relapses were more frequent with R-CHOP. During induction, cytopenias were significantly more frequent with R-CHOP and so was the use of colony-stimulating factors. During maintenance therapy, R-B showed more neutropenia and infectious toxicity. After a median follow-up of 81 months (95% CI: 77–86), the 6-year rates of progression-free survival (PFS) were 79% (95% CI: 72–86) for R-bendamustine vs. 67% (95% CI: 61–73) for R-CHOP (p = 0.046), and 6-year overall survival (OS) values were 91% (95% CI: 86–96) for R-B vs. 91% (95% CI: 87–94) for R-CHOP (p = 0.49). In conclusion, R-B followed by rituximab maintenance therapy in patients with previously untreated FL resulted in significantly longer PFS than R-CHOP, with older patients also benefiting from this treatment without further toxicity. Adverse events during maintenance were more frequent with R-B without impacting mortality.

oncology

What problem does this paper attempt to address?

### Problems the paper attempts to solve

This paper aims to compare the efficacy of R - Bendamustine (R - B) and R - CHOP (R - cyclophosphamide, doxorubicin, vincristine and prednisone) plus maintenance therapy as first - line systemic treatments for follicular lymphoma (FL). Specifically, the researchers hope to answer the following questions:

1. **Efficacy comparison**:
- Is there a difference in the complete remission rate (CR) between R - Bendamustine and R - CHOP after induction therapy?
- After maintenance therapy, how do the progression - free survival (PFS) and overall survival (OS) of the two regimens differ?

2. **Toxicity comparison**:
- How do the toxicity reactions (such as neutropenia, infection, etc.) of the two regimens during induction therapy and maintenance therapy differ?
- Is there a regimen that is safer in elderly patients?

3. **Necessity of maintenance therapy**:
- After treatment with R - Bendamustine and R - CHOP, is maintenance therapy equally effective?
- For patients who achieve complete remission (CR), is maintenance therapy necessary?

### Research background

Follicular lymphoma is a common indolent lymphoma, accounting for approximately 30% of all non - Hodgkin lymphomas. Although its overall survival exceeds 10 years, follicular lymphoma is still an incurable hematological malignancy and often has multiple relapses. Currently, R - CHOP and R - Bendamustine are common initial treatment regimens. Maintenance therapy with rituximab after R - CHOP induction therapy has been proven to significantly improve the progression - free survival (PFS) of patients, but it is not clear whether maintenance therapy is also applicable after R - Bendamustine.

### Research methods

This is a multicenter, retrospective observational study that included 476 follicular lymphoma patients from 17 GELTAMO centers. All patients received R - CHOP or R - Bendamustine as first - line treatment and were planned for two - year rituximab maintenance therapy. The primary endpoints of the study were progression - free survival (PFS) and overall survival (OS), and the secondary endpoints included complete remission rate (CR), toxicity reactions, etc.

### Main results

1. **Efficacy**:
- After the end of induction therapy, the complete remission rate (CR) in the R - Bendamustine group was higher (85% vs. 73%, p = 0.014).
- After a median follow - up of 81 months, the 6 - year progression - free survival (PFS) in the R - Bendamustine group was 79% (95% CI: 72–86), while that in the R - CHOP group was 67% (95% CI: 61–73), with a significant difference (p = 0.046).
- The 6 - year overall survival (OS) of the two groups was similar, both 91% (95% CI: 86–96 vs. 87–94, p = 0.49).

2. **Toxicity**:
- During induction therapy, cytopenia was more common in the R - CHOP group (p < 0.001), while the incidence of infection was higher in the R - Bendamustine group (p = 0.001).
- During maintenance therapy, severe neutropenia and infection were more common in the R - Bendamustine group (p < 0.001).

3. **Necessity of maintenance therapy**:
- The toxicity reactions in the R - Bendamustine group were more frequent during maintenance therapy, but there was no significant difference in mortality.
- For patients who achieve complete remission (CR), maintenance therapy may still be beneficial, but the specific effect needs further study.

### Conclusion

R - Bendamustine combined with rituximab maintenance therapy shows better progression - free survival (PFS) in untreated follicular lymphoma patients and does not increase additional toxicity in elderly patients. However, the toxicity reactions during maintenance therapy are more frequent but do not affect overall survival (OS). These results provide an important reference for further optimizing the treatment strategy for follicular lymphoma.